Peter J. Lenting

Peter J. Lenting

Auto-generated profile, based on publicly available information

Peter J. Lenting

Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Hémostase inflammation thrombose U1176, 94276, Le Kremlin-Bicêtre

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Neuron
Verified
Journal Article
Closed access
RDRashid Deane
Rashid Deane
ZWZhenhua Wu
Zhenhua Wu
ASAbhay Sagare
Abhay Sagare
JDJudianne Davis
Judianne Davis
SYShi Du Yan
Shi Du Yan
BZBerislav V. Zlokovic
Berislav V. Zlokovic

26 March 2015 in Blood
Verified
Journal Article
Open access
PDF file
PLPeter J. Lenting
Peter J. Lenting
OCOlivier Christophe
Olivier Christophe
CDCécile V. Denis
Cécile V. Denis
To understand the placement of a certain protein in a physiological system and the pathogenesis of related disorders, it is not only of interest to determine its function but also important to describe the sequential steps in its life cycle, from synthesis to secretion and ultimately its clearance. von Willebrand factor (VWF) is a particularly intriguing case in this regard because of its important auxiliary roles (both intra- and extracellular) that implicate a wide range of other proteins: its presence is required for the formation and regulated release of endothelial storage organelles, the Weibel-Palade bodies (WPBs), whereas VWF is also a key determinant in the clearance of coagulation factor VIII. Thus, understanding the molecular and cellular basis of the VWF life cycle will help us gain insight into the pathogenesis of von Willebrand disease, design alternative treatment options to prolong the factor VIII half-life, and delineate the role of VWF and coresidents of the WPBs in the prothrombotic and proinflammatory response of endothelial cells. In this review, an update on our current knowledge on VWF biosynthesis, secretion, and clearance is provided and we will discuss how they can be affected by the presence of protein defects.

12 August 2007 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ASAbhay Sagare
Abhay Sagare
RDRashid Deane
Rashid Deane
RBRobert D Bell
Robert D Bell
BJBradley Johnson
Bradley Johnson
KHKatie Hamm
Katie Hamm
BZBerislav V Zlokovic
Berislav V Zlokovic

1 June 1988 in Nature
Verified
Journal Article
Closed access
AKAlexander R. van der Krol
Alexander R. van der Krol
PLPeter E. Lenting
Peter E. Lenting
JVJetty Veenstra
Jetty Veenstra
IMIngrid M. van der Meer
Ingrid M. van der Meer
RKRonald E. Koes
Ronald E. Koes
ASAntoine R. Stuitje
Antoine R. Stuitje

5 June 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
RLRobert Jan Lebbink
Robert Jan Lebbink
TRTalitha de Ruiter
Talitha de Ruiter
JAJelle Adelmeijer
Jelle Adelmeijer
ABArjan B. Brenkman
Arjan B. Brenkman
JHJoop M. van Helvoort
Joop M. van Helvoort
LMLinde Meyaard
Linde Meyaard
Collagens are the most abundant proteins in the human body, important in maintenance of tissue structure and hemostasis. Here we report that collagens are high affinity ligands for the broadly expressed inhibitory leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1). The interaction is dependent on the conserved Gly-Pro-Hyp collagen repeats. Antibody cross-linking of LAIR-1 is known to inhibit immune cell function in vitro. We now show that collagens are functional ligands for LAIR-1 and directly inhibit immune cell activation in vitro. Thus far, all documented ligands for immune inhibitory receptors are membrane molecules, implying a regulatory role in cell–cell interaction. Our data reveal a novel mechanism of peripheral immune regulation by inhibitory immune receptors binding to extracellular matrix collagens.

25 April 2013 in Blood
Verified
Journal Article
Open access
PDF file
JMJenny McIntosh
Jenny McIntosh
PLPeter J. Lenting
Peter J. Lenting
CRCecilia Rosales
Cecilia Rosales
DLDoyoung Lee
Doyoung Lee
SRSamira Rabbanian
Samira Rabbanian
ANAmit C. Nathwani
Amit C. Nathwani
Key Points: Novel, more potent codon-optimized human FVIII variant (codop-hFVIII-V3). Codop-hFVIII-V3 is safe and efficacious in mice and nonhuman primates, thus improving the prospects of gene therapy for hemophilia A.